Efficacy and Safety of Empagliflozin (EMPA) in Younger, Overweight/Obese Patients with Type 2 Diabetes (T2DM) with HbA1c ≥8%

被引：0

|

作者：

Merker, Ludwig

Lund, Soren S.

Hantel, Stefan

Salsali, Afshin

Kim, Gabriel

Broedl, Uli C.

Woerle, Hans J.

Hach, Thomas

机构：

来源：

DIABETES | 2014年 / 63卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1079-P

引用

收藏

页码：A280 / A281

页数：2

相关论文

共 50 条

[21] Empagliflozin (EMPA) for ≥76 Weeks as Add-on to Pioglitazone With or Without Metformin in Patients with Type 2 Diabetes (T2DM)
Kovacs, Christopher S.
Seshiah, Veeraswamy
Merker, Ludwig
Christiansen, Anita Vedel
Roux, Flavien
Salsali, Afshin
Kim, Gabriel
Stella, Peter
Woerle, Hans J.
Broedl, Uli C.
DIABETES, 2014, 63 : A273 - A273
[22] An average HbA1C of <7.0 is achievable in patients with T2DM
Hood, RC
DIABETES, 2002, 51 : A485 - A485
[23] THE IMPORTANCE OF HBA1C EVOLUTION IN COST-EFFECTIVENESS MODELING OF TYPE 2 DIABETES MELLITUS (T2DM)
Willis, M.
He, J.
Neslusan, C.
Johansen, P.
Worbes-cerezo, M.
VALUE IN HEALTH, 2012, 15 (07) : A500 - A500
[24] Implications of Using the UKPDS HbA1c Equation in Economic Modeling of Type 2 Diabetes Mellitus (T2DM)
Willis, Michael
Asseburg, Christian
Johansen, Pierre
Schroeder, Melanie
Neslusan, Cheryl
DIABETES, 2016, 65 : A581 - A581
[25] Sustained reduction in HbA1c during one-year treatment with vildagliptin in patients with type 2 diabetes (T2DM)
Dejager, Sylvie
Lebeaut, Alexandre
Couturier, Andre
Schweizer, Anja
DIABETES, 2006, 55 : A29 - A29
[26] Effect of empagliflozin (EMPA) on diabetic ketoacidosis (DKA) in patients with type 2 diabetes (T2DM): pooled clinical trial data
Lund, S.
Solimando, F.
Kohler, S.
Zeller, C.
Kaspers, S.
DIABETOLOGIA, 2016, 59 : S26 - S27
[27] Efficacy and Safety of Vildagliptin in Triple Combination With Metformin Plus Sulfonylurea in Subgroup of Patients With T2DM and Baseline HbA1c
Lukashevich, Valentina
Araga, Mako
Kothny, Wolfgang
DIABETES, 2013, 62 : A294 - A294
[28] Empagliflozin (EMPA) for ≥76 Weeks as Add-on to Metformin Plus Sulfonylurea (SU) in Patients with Type 2 Diabetes (T2DM)
Haering, Hans-Ulrich
Merker, Ludwig
Vedel, Anita
Roux, Christiansen Flavien
Salsali, Afshin
Kim, Gabriel
Meinicke, Thomas
Woerle, Hans J.
Broedl, Uli C.
DIABETES, 2014, 63 : A280 - A280
[29] Empagliflozin (EMPA) Compared with Glimepiride (GLIM) as Add-on to Metformin (MET) for 2 Years in Patients with Type 2 Diabetes (T2DM)
Ridderstrale, Martin
Andersen, Knut Robert
Zeller, Cordula
Kim, Gabriel
Woerle, Hans J.
Broedl, Uli C.
DIABETES, 2014, 63 : A70 - A70
[30] Efficacy of orlistat in patients with type 2 diabetes with baseline HbA1c, levels ≥8%
Davidson, JA
Barnett, A
DIABETES, 2002, 51 : A95 - A95

← 1 2 3 4 5 →